# Fluoropyrimidine Tailored-dose Based on Uracil Concentration in Patients Treated for Digestive Carcinomas: Evaluation of Clinical Practice

> **NCT04918264** · — · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 334 (actual)

## Conditions studied

- Digestive Carcinoma

## Interventions

- **DRUG:** Fluoropyrimidine treatment (5-FU or capecitabine) and dosage
- **OTHER:** Uracil dosage
- **BEHAVIORAL:** Overall survival

## Key facts

- **NCT ID:** NCT04918264
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-02
- **Primary completion:** 2021-02-10
- **Final completion:** 2021-04-15
- **Target enrollment:** 334 (ACTUAL)
- **Last updated:** 2021-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04918264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04918264, "Fluoropyrimidine Tailored-dose Based on Uracil Concentration in Patients Treated for Digestive Carcinomas: Evaluation of Clinical Practice". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04918264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*